The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
FGF-21 as a novel metabolic regulator
Open accessAbstract
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, FGF21 stimulates the uptake of glucose by adipocytes and inhibits the production of glucose in the liver.”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FGF21 acts in the control of glucose and lipid homeostasis (Kharitonenkov et al., 2005).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, FGF21 appears to protect pancreatic β cells from cell death induced by glycotoxicity (Kharitonenkov et al., 2005, 2007).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, mice that overexpress FGF-21, a circulating FGF which is induced by a ketogenic diet 106, are lean and have increased brown fat 107, suggesting that the beneficial metabolic effects induced by a ketogenic diet are brought about in part by increases in BAT mass.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [107]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“overexpression of FGF21 is highly protective [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“activation of the FGF21/FGFR1c/KLB receptor complex results in the phosphorylation of ERK1/2 and FRS2α [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In rodents, pharmacological levels of FGF21 increase energy expenditure (64, 141), which results in increased food intake (54, 64).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In addition, FGF21 enhances insulin sensitivity in primary brown adipocytes (86) but not in primary white adipocytes (64, 86).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [114]
In the citing paper
“Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine 61 and has been shown to be necessary for the adaptation to fasting 62, 63.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
SIGNALLING BY RECEPTOR TYROSINE KINASES
Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.453 · Cited by 1,118
Cheatham, B., Vlahos, C. J., Cheatham, L. A., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902-4911.1994 · Cited by 1,062
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Flagged first, then by citations
Research works printed but not linked: 3
- Konishi, 1999, J. Biol. Chem., 255, 12119
- Shah, 2000, J. Clin. Endocrinol. Metab., 85, 4053
- Cheatham, 1994, Mol. Cell. Biol., 14, 4902, 10.1128/MCB.14.7.4902 · DOI
Cited by
Sorted by citations
Items 201–300 of 1,008
Wu, A.-L., Coulter, S., Liddle, C., Wong, A., Eastham‐Anderson, J., French, D. M., Peterson, A. S., & Sonoda, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017868 · Cited by 185
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
Hale, C., Chen, M. M., Stanislaus, S., Chinookoswong, N., Hager, T., Wang, M., Véniant, M. M., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2010-1262 · Cited by 185
Nrf2 Represses FGF21 During Long-Term High-Fat Diet–Induced Obesity in Mice
Chartoumpekis, D. V., Ziros, P. G., Psyrogiannis, A. I., Papavassiliou, A. G., Kyriazopoulou, V. E., Sykiotis, G. P., & Habeos, I. G. (2011) · Diabetes · doi:10.2337/db11-0112 · Cited by 186
Jiang, S., Cheng, Y., Fang, Q., Shao, M., Zhang, Y., Liu, Y., Deng, Y., Shan, B., Liu, J., Li, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.565960 · Cited by 182
Ge, X., Chen, C., Hui, X. H., Wang, Y., Lam, K. S. L., & Xu, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248591 · Cited by 181
Mirza, M. A. I., Alsiö, J., Hammarstedt, A., Erben, R. G., Michaëlsson, K., Tivesten, Å., Marsell, R., ORWOLL, E. S., Karlsson, M. K., Ljunggren, Ö., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.214619 · Cited by 182
High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes
Chen, C., Cheung, B. M. Y., Tso, A. W. K., Wang, Y., Law, L. S., Ong, K. L., Wat, N. M. S., Xu, A., & Lam, K. S. L. (2011) · Diabetes Care · doi:10.2337/dc11-0294 · Cited by 181
Wang, H., Qiang, L., & Farmer, S. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00992-07 · Cited by 181
Yu, Y.-H., He, J., Li, S., Song, L., Guo, X., Yao, W., Zou, D., Gao, X., Liu, Y., Bai, F., et al. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.026 · Cited by 182
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
Lynch, L., Hogan, A. E., Duquette, D., Lester, C., Banks, A. S., LeClair, K. B., Cohen, D. E., Ghosh, A., Lü, B., Corrigan, M. A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.003 · Cited by 185
FGF21 Requires βklotho to Act In Vivo
Adams, A. C., Cheng, C. C., Coskun, T., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049977 · Cited by 181
Self-citationEndocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose Tissue
Liu, S. Q., Roberts, D., Kharitonenkov, A., Zhang, B., Hanson, S., Li, Y. C., Zhang, L., & Wu, Y. (2013) · Scientific Reports · doi:10.1038/srep02767 · Cited by 179
Fibroblast Growth Factor 21 Reduces the Severity of Cerulein-Induced Pancreatitis in Mice
Johnson, C. L., Weston, J. Y., Chadi, S. A., Fazio, E. N., Huff, M. W., Kharitonenkov, A., Köester, A., & Pin, C. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.064 · Cited by 180
Lin, Z., Wu, Z., Yin, X., Liu, Y., Yan, X., Lin, S., Xiao, J., Wang, X., Feng, W., & Li, X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015534 · Cited by 179
Exercise increases serum fibroblast growth factor 21 (FGF21) levels
Cuevas-Ramos, D., Almeda-Valdés, P., Meza-Arana, C. E., Brito-Córdova, G., Gómez-Pérez, F. J., Mehta, R., Oseguera-Moguel, J., & Aguilar-Salinas, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038022 · Cited by 178
Inter‐organ communication: a gatekeeper for metabolic health
Castillo‐Armengol, J., Fajas, L., & Lopez‐Mejia, I. C. (2019) · The EMBO Reports · doi:10.15252/embr.201947903 · Cited by 178
Li, H., Wu, G., Fang, Q., Zhang, M., Hui, X., Sheng, B., Wu, L., Bao, Y., Li, P., Xu, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02677-9 · Cited by 178
The REV-ERBs and RORs: Molecular Links Between Circadian Rhythms and Lipid Homeostasis
Solt, L. A., Kojetin, D. J., & Burris, T. P. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.9 · Cited by 177
Insulin resistance in type 2 diabetes mellitus
Accili, D., Deng, Z., & Liu, Q. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01114-y · Cited by 219
Wu, A.-L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., Phamluong, K., Feng, B., Li, L., Marsters, S., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002669 · Cited by 184
Liver governs adipose remodelling via extracellular vesicles in response to lipid overload
Zhao, Y., Zhao, M., Jiang, S., Wu, J., Liu, J., Yuan, X., Shen, D., Zhang, J., Zhou, N., He, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14450-6 · Cited by 181
Lactate as a Signaling Molecule That Regulates Exercise-Induced Adaptations
Nalbandian, M., & Takeda, M. (2016) · Biology · doi:10.3390/biology5040038 · Cited by 174
Townsend, K. L., & Tseng, Y. (2012) · Adipocyte · doi:10.4161/adip.18951 · Cited by 182
Metabolic implications of organelle–mitochondria communication
Gordaliza‐Alaguero, I., Cantó, C., & Antonio Zorzano, A. (2019) · EMBO Reports · doi:10.15252/embr.201947928 · Cited by 177
Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W. L., & Luo, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033870 · Cited by 173
Gong, Q., Hu, Z., Zhang, F., Cui, A., Chen, X., Jiang, H., Gao, J., Chen, X., Han, Y., Liang, Q., et al. (2016) · Hepatology · doi:10.1002/hep.28523 · Cited by 171
Win, S., Than, T. A., Zhang, J., Oo, C., Min, R. W. M., & Kaplowitz, N. (2017) · Hepatology · doi:10.1002/hep.29689 · Cited by 171
Yu, H., Xia, F., Lam, K. S., Wang, Y., Bao, Y., Zhang, J., Gu, Y., Zhou, P., Lu, J., Jia, W., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155184 · Cited by 170
FGF19 subfamily members: FGF19 and FGF21
Dołęgowska, K., Marchelek‐Myśliwiec, M., Nowosiad-Magda, M., Sławiński, M., & Dołęgowska, B. (2019) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-019-00675-7 · Cited by 175
LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys
Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065763 · Cited by 169
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
Kharitonenkov, A., Beals, J. M., Micanovic, R., Strifler, B. A., Rathnachalam, R., Wroblewski, V. J., Li, S., Köester, A., Ford, A. M., Coşkun, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058575 · Cited by 168
Gómez‐Ambrosi, J., Gallego-Escuredo, J. M., Catalán, V., Rodrı́guez, A., Domingo, P., Moncada, R., Valentí, V., Salvador, J., Giralt, M., Villarroya, F., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.04.027 · Cited by 168
Hecht, R. I., Li, Y., Sun, J., Belouski, E., Hall, M. P., Hager, T., Yie, J., Wang, W., Winters, D., Smith, S. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049345 · Cited by 166
Going Back to the Biology of FGF21: New Insights
Lewis, J. E., Ebling, F. J. P., Samms, R. J., & Tsintzas, K. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.05.007 · Cited by 170
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism
Fisher, F. M., Kim, M., Doridot, L., Cunniff, J. C., Parker, T. S., Levine, D. M., Hellerstein, M. K., Hudgins, L. C., Maratos-Flier, E., & Herman, M. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.008 · Cited by 166
Fibroblast growth factor 21 is induced by endoplasmic reticulum stress
Schaap, F. G., Kremer, A. E., Lamers, W. H., Jansen, P. L. M., & Gaemers, I. C. (2012) · Biochimie · doi:10.1016/j.biochi.2012.10.019 · Cited by 164
Pan, X., Shao, Y., Wu, F., Wang, Y., Xiong, R., Zheng, J., Tian, H., Wang, B., Wang, Y., Zhang, Y., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.002 · Cited by 163
FGF21-based pharmacotherapy – potential utility for metabolic disorders
Gimeno, R. E., & Moller, D. E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.03.001 · Cited by 163
Contreras, C., González, F., Fernø, J., Diéguez, C., Rahmouni, K., Nogueiras, R., & López, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.919727 · Cited by 167
Fibroblast growth factor 21 and its novel association with oxidative stress
Gómez-Sámano, M. Á., Grajales-Gómez, M., Zuarth-Vázquez, J. M., Navarro-Flores, M. F., Martínez-Saavedra, M., Juárez-León, Ó. A., Morales-García, M., Enriquez-Estrada, V. M., Gomez-Perez, F. J., & Ramos, D. C. (2016) · Redox Biology · doi:10.1016/j.redox.2016.12.024 · Cited by 168
Mu, J., Pinkstaff, J. K., Li, Z., Skidmore, L. K., Li, N., Myler, H. A., Dallas-Yang, Q., Hays, A. A., Yao, J., Bussell, S., et al. (2011) · Diabetes · doi:10.2337/db11-0838 · Cited by 162
Carbohydrate Sensing Through the Transcription Factor ChREBP
Ortega-Prieto, P., & Postic, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00472 · Cited by 163
Cyphert, H. A., Ge, X., Kohan, A. B., Salati, L. M., Zhang, Y., & Hillgartner, F. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.375907 · Cited by 162
Reinehr, T., Woelfle, J., Wunsch, R., & Roth, C. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1221 · Cited by 160
Kumar, V., Xin, X., Ma, J., Tan, C., Osna, N. A., & Mahato, R. I. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113888 · Cited by 165
Exercise-Released Myokines in the Control of Energy Metabolism
Laurens, C., Bergouignan, A., & Moro, C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00091 · Cited by 159
The Role of PPAR α Activation in Liver and Muscle
Burri, L., Thoresen, G. H., & Berge, R. K. (2010) · PPAR Research · doi:10.1155/2010/542359 · Cited by 173
Mai, K., Andres, J., Biedasek, K., Weicht, J., Bobbert, T., Sabath, M., Meinus, S., Reinecke, F., Möhlig, M., Weickert, M. O., et al. (2009) · Diabetes · doi:10.2337/db08-1775 · Cited by 159
Wang, C., Niederstrasser, H., Douglas, P. M., Lin, R., Jaramillo, J., Li, Y., Oswald, N. W., Zhou, A., McMillan, E. A., Mendiratta, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02332-3 · Cited by 158
LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance
Lan, F., Misu, H., Chikamoto, K., Takayama, H., Kikuchi, A., Mohri, K., Takata, N., Hayashi, H., Matsuzawa-Nagata, N., Takeshita, Y., et al. (2014) · Diabetes · doi:10.2337/db13-0728 · Cited by 158
Determinants of GH resistance in malnutrition
Fazeli, P. K., & Klibanski, A. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0477 · Cited by 168
Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156
Insulin Resistance and Mitochondrial Dysfunction
González-Franquesa, A., & Patti, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_25 · Cited by 160
van Deuren, T., Blaak, E. E., & Canfora, E. E. (2022) · Obesity Reviews · doi:10.1111/obr.13498 · Cited by 169
Identification of MUP1 as a Regulator for Glucose and Lipid Metabolism in Mice
Zhou, Y., Jiang, L., & Rui, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900754200 · Cited by 154
Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1
Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.046 · Cited by 154
Self-citationSpatial transcriptomic landscape unveils immunoglobin-associated senescence as a hallmark of aging
Ma, S., Ji, Z., Zhang, B., Geng, L., Cai, Y., Nie, C., Li, J., Zuo, Y., Sun, Y., Xu, G., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.019 · Cited by 162
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0111 · Cited by 153
Sun, Y., Xia, M., Yan, H., Han, Y., Zhang, F., Hu, Z., Cui, A., Ma, F., Liu, Z., Gong, Q., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14079 · Cited by 152
FGF21 N‐ and C‐termini play different roles in receptor interaction and activation
Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S., et al. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.11.023 · Cited by 149
FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance
Szczepańska, E., & Gietka‐Czernel, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1778-4159 · Cited by 155
Desai, B. N., Singhal, G., Watanabe, M., Stevanovic, D., Lundasen, T., Fisher, F. M., Mather, M. L., Vardeh, H. G., Douris, N., Adams, A. C., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.004 · Cited by 150
The role of bile acids in metabolic regulation
Vítek, L., & Haluzík, M. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0469 · Cited by 157
Fibroblast growth factor 21 and browning of white adipose tissue
Cuevas-Ramos, D., Mehta, R., & Aguilar-Salinas, C. A. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00037 · Cited by 149
Fibroblast growth factor-21, energy balance and obesity
Giralt, M., Gavaldà‐Navarro, A., & Villarroya, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.018 · Cited by 150
Feige, J. N., Gerber, A., Casals‐Casas, C., Yang, Q., Winkler, C., Bedu, E., Bueno, M., Gelman, L., Auwerx, J. H., Gonzalez, F. J., et al. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0901217 · Cited by 148
Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys
Véniant, M. M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. I., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2012-1211 · Cited by 148
Huang, Z., Zhong, L., Lee, J. T. H., Zhang, J., Wu, D., Geng, L., Wang, Y., Wong, C.-M., & Xu, A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.003 · Cited by 147
FGF21 reloaded: challenges of a rapidly growing field
Kharitonenkov, A., & Larsen, P. J. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.11.003 · Cited by 147
Yang, S. J., Hong, H. C., Choi, H. Y., Yoo, H. J., Cho, G. J., Hwang, T. G., Baik, S. H., Choi, D. S., Kim, S. M., & Choi, K. M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04078.x · Cited by 147
New developments in the biology of fibroblast growth factors
Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 147
Structural basis for FGF hormone signalling
Chen, L., Fu, L., Sun, J., Huang, Z., Fang, M., Zinkle, A., Liu, X., Lu, J., Pan, Z., Wang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06155-9 · Cited by 147
Mitophagy Directs Muscle-Adipose Crosstalk to Alleviate Dietary Obesity
Fu, T., Xu, Z., Liu, L., Guo, Q., Wu, H., Liang, X., Zhou, D., Xiao, L., Liu, L., Liu, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.127 · Cited by 145
Different roles of N‐ and C‐ termini in the functional activity of FGF21
Micanovic, R., Raches, D. W., Dunbar, J. D., Driver, D. A., Bina, H. A., Dickinson, C. D., & Kharitonenkov, A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21675 · Cited by 146
Kim, K. H., & Lee, M.-S. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.245 · Cited by 146
Inak, G., Rybak‐Wolf, A., Lisowski, P., Pentimalli, T. M., Jüttner, R., Glažar, P., Uppal, K., Bottani, E., Brunetti, D., Secker, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22117-z · Cited by 151
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 145
Relevant use of Klotho in FGF19 subfamily signaling system in vivo
Tomiyama, K.-I., Maeda, R., Urakawa, I., Yamazaki, Y., Tanaka, T., Ito, S., Nabeshima, Y., Tomita, T., Odori, S., Hosoda, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913986107 · Cited by 144
Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice
Kim, H. W., Lee, J. E., Cha, J. J., Hyun, Y. Y., Kim, J. E., Lee, M. H., Song, H. K., Nam, D. H., Han, J., Han, S. Y., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2276 · Cited by 142
Lee, P., Brychta, R. J., Linderman, J. D., Smith, S., Chen, K. Y., & Celi, F. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3107 · Cited by 142
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142
“In 2005, fibroblast growth factor 21 (FGF21), a hormone secreted from the liver, was described as a novel metabolic regulator (75).”
BackgroundFGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice
Véniant, M. M., Hale, C., Helmering, J., Chen, M. M., Stanislaus, S., Busby, J., Vonderfecht, S., Xu, J., & Lloyd, D. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040164 · Cited by 141
Chen, W., Hoo, R. L. C., Konishi, M., Itoh, N., Lee, P.-C., Ye, H., Lam, K. S. L., & Xu, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.285965 · Cited by 141
Adams, A. C., Astapova, I. I., Fisher, F. M., Badman, M. K., Kurgansky, K. E., Flier, J. S., Hollenberg, A. N., & Maratos–Flier, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.107375 · Cited by 141
Li, X. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0711-y · Cited by 143
Pan, Q., Lin, S., Li, Y., Liu, L., Li, X., Gao, X., Yan, J., Gu, B., Chen, X., Li, W., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103202 · Cited by 138
Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling
Wu, X., Ge, H., Gupte, J., Weiszmann, J., Shimamoto, G., Stevens, J., Hawkins, N., Lemon, B., Shen, W., Xu, J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700130200 · Cited by 140
Wang, L., Ishihara, T., Ibayashi, Y., Tatsushima, K., Setoyama, D., Hanada, Y., Takeichi, Y., Sakamoto, S., Yokota, S., Mihara, K., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3704-7 · Cited by 138
Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review
Eshraghian, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i25.8102 · Cited by 145
Wanders, D., Stone, K. P., Forney, L. A., Cortez, C. C., Dille, K. N., Simon, J., Xu, M., Hotard, E. C., Nikonorova, I. A., Pettit, A. P., et al. (2016) · Diabetes · doi:10.2337/db15-1324 · Cited by 138
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
Pοlyzos, S. A., Kang, E. S., Boutari, C., Rhee, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154203 · Cited by 144
Endocrine FGFs and Klothos: emerging concepts
Kuro‐o, M. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.06.002 · Cited by 141
FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
Huang, X., Yang, C., Luo, Y., Jin, C., Wang, F., & McKeehan, W. L. (2007) · Diabetes · doi:10.2337/db07-0648 · Cited by 137
Scherer, P. E. (2016) · Diabetes · doi:10.2337/db16-0339 · Cited by 133
“Additional molecules, such as resistin (25,26), fibroblast growth factor 21 (FGF21) (27), and endotrophin (28), were added to that list of adipocyte-enriched secretory products at later points by us and others (Fig.”
InfluentialFibroblast Growth Factor Signaling in Metabolic Regulation
Nies, V. J. M., Sancar, G., Liu, W., van Zutphen, T., Struik, D., Yu, R. T., Atkins, A. R., Evans, R. M., Jonker, J. W., & Downes, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00193 · Cited by 137
Metabolic Messengers: fibroblast growth factor 15/19
Gadaleta, R. M., & Moschetta, A. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0074-3 · Cited by 138
Fibroblast growth factor 21 in non-alcoholic fatty liver disease
Tucker, B., Li, H., Long, X., Rye, K., & Ong, K. L. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153994 · Cited by 132
Wanders, D., Forney, L. A., Stone, K. P., Burk, D. H., Pierse, A., & Gettys, T. W. (2017) · Diabetes · doi:10.2337/db16-1212 · Cited by 137
Exercise-induced myokines in health and metabolic diseases
So, B., Kim, H., Kim, J., & Song, W. J. (2014) · Integrative Medicine Research · doi:10.1016/j.imr.2014.09.007 · Cited by 139
Kim, H., Méndez, R., Zheng, Z., Chang, L., Cai, J., Zhang, R., & Zhang, K. (2014) · Endocrinology · doi:10.1210/en.2013-1490 · Cited by 134
Metadata
- Authors
- Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D.-S., Mehrbod, F., Jaskunas, S. R., & Shanafelt, A. B.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1627-1635
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1088017
- OpenAlex
- W2000665430
- Cited by
- 2,125
- References
- 46
- Citations by year
- 2026: 72 · 2025: 99 · 2024: 111 · 2023: 120 · 2022: 137 · 2021: 138 · 2020: 116 · 2019: 136 · 2018: 147 · 2017: 135 · 2016: 142 · 2015: 155 · 2014: 124 · 2013: 125 · 2012: 115
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Hospital for Sick Children
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, diabetes mellitus, glucose uptake, adipocytes, diet-induced obesity, transgenic mice, ob/ob mice, db/db mice, plasma glucose, triglycerides, metabolic regulation, diabetes treatment
- MeSH terms
- Animals, Blood Glucose, Cell Division, Cells, Cultured, Diabetes Mellitus, Fibroblast Growth Factors, Humans, Hyperglycemia, Hypoglycemic Agents, Mice, Obese, Mice, Transgenic, Triglycerides, Weight Gain, Adipocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
